Document is current
Any future updates will be listed below
-
Authors
Yang, Rui
Elsaadi, Samah
Misund, Kristine
Abdollahi, Pegah
Vandsemb, Esten Nymoen
Moen, Siv Helen
Kusnierczyk, Anna
Slupphaug, Geir
Standal, Therese
Waage, Anders
Slørdahl, Tobias S
Rø, Torstein Baade
Rustad, Even
Sundan, Anders
Hay, Carl
Cooper, Zachary https://orcid.org/0000-0003-1059-0940
Schuller, Alwin G
Woessner, Richard
Borodovsky, Alexandra
Menu, Eline
Børset, Magne
Sponaas, Anne Marit https://orcid.org/0000-0002-0860-8446
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02503774 at ClinicalTrials.govnct02740985 at ClinicalTrials.govDocuments that mention this clinical trial
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
https://doi.org/10.1136/jitc-2020-000610
nct03454451 at ClinicalTrials.govDocuments that mention this clinical trial
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
https://doi.org/10.1136/jitc-2020-000610
nct03454451 at ClinicalTrials.govDocuments that mention this clinical trial
High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
https://doi.org/10.1136/jitc-2020-001965
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
https://doi.org/10.1136/jitc-2020-001467
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
https://doi.org/10.1136/jitc-2020-000610
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
https://doi.org/10.1136/jitc-2022-005802
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
https://doi.org/10.1136/jitc-2022-004554
nct02503774 at ClinicalTrials.govDocuments that mention this clinical trial
High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
https://doi.org/10.1136/jitc-2020-001965
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
https://doi.org/10.1136/jitc-2020-001467
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
https://doi.org/10.1136/jitc-2020-000610
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
https://doi.org/10.1136/jitc-2022-005802
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
https://doi.org/10.1136/jitc-2022-004554
Documents that mention this clinical trial
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy
https://doi.org/10.1136/jitc-2021-004089
Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
https://doi.org/10.1136/jitc-2020-000610
- License Information
